S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:COGT

Cogent Biosciences (COGT) Stock Forecast, Price & News

$11.23
+0.03 (+0.27%)
(As of 05/26/2023 ET)
Compare
Today's Range
$10.90
$11.32
50-Day Range
$9.85
$12.13
52-Week Range
$4.13
$18.07
Volume
397,584 shs
Average Volume
735,627 shs
Market Capitalization
$796.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.60

Cogent Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
92.3% Upside
$21.60 Price Target
Short Interest
Healthy
6.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Cogent Biosciences in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.22) to ($2.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

579th out of 1,012 stocks

Pharmaceutical Preparations Industry

282nd out of 495 stocks


COGT stock logo

About Cogent Biosciences (NASDAQ:COGT) Stock

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Receive COGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

COGT Stock News Headlines

Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
SVB Securities Keeps Their Buy Rating on Cogent Biosciences (COGT)
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Cogent Biosciences (NASDAQ:COGT) Shares Up 4.4%
Cogent Biosciences (COGT) Gets a Buy from SVB Securities
Needham Sticks to Their Buy Rating for Cogent Biosciences (COGT)
4 Analysts Have This to Say About Cogent Biosciences
LifeSci Capital Keeps Their Buy Rating on Cogent Biosciences (COGT)
See More Headlines
Receive COGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

COGT Company Calendar

Last Earnings
3/14/2023
Today
5/28/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COGT
Fax
N/A
Employees
77
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.60
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+92.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-140,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.87 million
Book Value
$2.27 per share

Miscellaneous

Free Float
68,109,000
Market Cap
$796.77 million
Optionable
Not Optionable
Beta
1.71

Key Executives

  • Andrew R. Robbins
    President, Chief Executive Officer & Director
  • John L. GreenJohn L. Green
    Chief Financial & Accounting Officer
  • Jessica Sachs
    Chief Medical Officer
  • John Edward Robinson
    Chief Scientific Officer
  • Rachael Easton
    Vice President & Head-Clinical Development













COGT Stock - Frequently Asked Questions

Should I buy or sell Cogent Biosciences stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" COGT shares.
View COGT analyst ratings
or view top-rated stocks.

What is Cogent Biosciences' stock price forecast for 2023?

5 brokers have issued twelve-month price targets for Cogent Biosciences' shares. Their COGT share price forecasts range from $19.00 to $26.00. On average, they predict the company's share price to reach $21.60 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts price targets for COGT
or view top-rated stocks among Wall Street analysts.

How have COGT shares performed in 2023?

Cogent Biosciences' stock was trading at $11.56 on January 1st, 2023. Since then, COGT shares have decreased by 2.9% and is now trading at $11.23.
View the best growth stocks for 2023 here
.

Are investors shorting Cogent Biosciences?

Cogent Biosciences saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 4,510,000 shares, a drop of 15.1% from the April 30th total of 5,310,000 shares. Based on an average daily trading volume, of 643,200 shares, the days-to-cover ratio is currently 7.0 days.
View Cogent Biosciences' Short Interest
.

When is Cogent Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our COGT earnings forecast
.

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:COGT) issued its earnings results on Tuesday, March, 14th. The technology company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.06.

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM).

What is Cogent Biosciences' stock symbol?

Cogent Biosciences trades on the NASDAQ under the ticker symbol "COGT."

Who are Cogent Biosciences' major shareholders?

Cogent Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.11%), Commodore Capital LP (6.73%), State Street Corp (4.83%), Perceptive Advisors LLC (3.22%), Suvretta Capital Management LLC (2.56%) and Geode Capital Management LLC (1.86%). Insiders that own company stock include Fairmount Funds Management Llc and John L Green.
View institutional ownership trends
.

How do I buy shares of Cogent Biosciences?

Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cogent Biosciences' stock price today?

One share of COGT stock can currently be purchased for approximately $11.23.

How much money does Cogent Biosciences make?

Cogent Biosciences (NASDAQ:COGT) has a market capitalization of $796.77 million and generates $7.87 million in revenue each year. The technology company earns $-140,240,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

How can I contact Cogent Biosciences?

Cogent Biosciences' mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The official website for the company is www.cogint.com. The technology company can be reached via phone at (617) 945-5576 or via email at jkopin@cogint.com.

This page (NASDAQ:COGT) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -